Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

28266

Sigma-Aldrich

Levofloxacin

98.0-102.0% anhydrous basis (HPLC)

Sinónimos:

Levofloxacin Anhydrous, (−)-Ofloxacin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H20FN3O4
Número de CAS:
100986-85-4
Peso molecular:
361.37
Beilstein:
7327015
Número MDL:
MFCD00865049
Código UNSPSC:
51102829
ID de la sustancia en PubChem:
57648297
NACRES:
NA.85

origen biológico

synthetic

Nivel de calidad

200

Ensayo

98.0-102.0% anhydrous basis (HPLC)

Formulario

powder or crystals

color

light yellow-white to yellow-white

espectro de actividad antibiótica

Gram-negative bacteria
Gram-positive bacteria

Modo de acción

enzyme | inhibits

cadena SMILES

OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

Clave InChI

GSDSWSVVBLHKDQ-JTQLQIEISA-N

Información sobre el gen

human ... KCNH1(3756)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Aplicación

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic , antibiotic resistance , and resistance prevention studies. Antibiotic against bacterial respiratory tract infections.

Acciones bioquímicas o fisiológicas

Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

Envase

10mg, 1g, 10g

Otras notas

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palabra de señalización

Danger

Frases de peligro

H302,H317,H334

Clasificaciones de peligro

Acute Tox. 4 Oral - Resp. Sens. 1A - Skin Sens. 1A

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000417206
0000417206
0000381693
0000381693
0000340342

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

George G Zhanel et al.
Drugs, 62(1), 13-59 (2002-01-16)
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still maintains the best in vitro activity
Miriam Hurst et al.
Drugs, 62(14), 2127-2167 (2002-09-25)
Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less
Takeshi Hirano et al.
International journal of pharmaceutics, 351(1-2), 113-118 (2007-11-06)
L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner membrane followed by fatty acid beta-oxidation. It is known that members of the OCTN family play an important role in
M H Gotfried et al.
Chest, 119(4), 1114-1122 (2001-04-11)
To determine the steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Multiple-dose, open-label, randomized pharmacokinetic study. Thirty-six healthy, nonsmoking adult subjects were randomized either to oral levofloxacin, 500 or 750 mg once daily
Gregory S Basarab et al.
Scientific reports, 5, 11827-11827 (2015-07-15)
With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea
Ver todos los artículos relacionados

Artículos

Inhibition of Nucleic Acid Synthesis by Antibiotics

Explore how antibiotics, particularly quinolones, inhibit nucleic acid synthesis by targeting topoisomerases, crucial for DNA replication processes.

Inhibition of Nucleic Acid Synthesis by Antibiotics

Explore how antibiotics, particularly quinolones, inhibit nucleic acid synthesis by targeting topoisomerases, crucial for DNA replication processes.

Inhibition of Nucleic Acid Synthesis by Antibiotics

Explore how antibiotics, particularly quinolones, inhibit nucleic acid synthesis by targeting topoisomerases, crucial for DNA replication processes.

Inhibition of Nucleic Acid Synthesis by Antibiotics

Explore how antibiotics, particularly quinolones, inhibit nucleic acid synthesis by targeting topoisomerases, crucial for DNA replication processes.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico